Despite their elevated risk for developing cervical, oropharyngeal, and other human papillomavirus (HPV)–related cancers and the strong and consistent evidence for the HPV vaccine’s safety and efficacy, many young cancer survivors reject this vaccine. In a new study appearing in Cancer, researchers from Emory University School of Medicine and the Aflac Cancer & Blood Disorders Center (both in Atlanta, Georgia), the University of Alabama at Birmingham, and St. Jude Children’s Research Hospital (Memphis, Tennessee) investigate the reasons that many young survivors are rejecting this vaccine (doi:10.1002/cncr.34521).

Senior study author Wendy Landier, PhD, a professor in the Division of Pediatric Hematology/Oncology and deputy director of the Institute for Cancer Outcomes and Survivorship at the University of Alabama at Birmingham Marnix E. Heersink School of Medicine, says that this is the first study to systematically characterize reasons for HPV vaccine refusal by a large group of young cancer survivors (or their parents).

尽管患宫颈癌、口咽癌和其他人乳头瘤病毒 (HPV) 相关癌症的风险较高，并且有强有力且一致的证据证明 HPV 疫苗的安全性和有效性，但许多年轻的癌症幸存者拒绝使用这种疫苗。在《癌症》杂志上发表的一项新研究中，来自埃默里大学医学院、Aflac 癌症和血液疾病中心（均位于佐治亚州亚特兰大）、阿拉巴马大学伯明翰分校和圣裘德儿童研究医院（田纳西州孟菲斯）的研究人员调查许多年轻幸存者拒绝这种疫苗的原因 (doi:10.1002/cncr.34521)。

资深研究作者 Wendy Landier 博士是阿拉巴马大学伯明翰分校 Marnix E. Heersink 医学院儿科血液学/肿瘤学部教授、癌症结果和生存研究所副所长，她说这是第一个一项研究系统地描述了一大群年轻癌症幸存者（或其父母）拒绝接种 HPV 疫苗的原因。